MSB 2.67% $1.10 mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-85

  1. 331 Posts.
    lightbulb Created with Sketch. 365
    The way the announcement made no mention of the adult trial makes me think that the company’s sense is that this might become a full approval which is not conditional on the adult trial commencing, even though it will be happening anyway.. (Remember it won’t cost much because of the BNT-CTN involvement but if successful will vastly expand the market.)

    Hope this is the first of many goals being kicked.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.